Effect of MAPK activation via mutations in NRAS , KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma
Hematological Oncology · 2023-12 · 41 (5) · 912-921
DOI: 10.1002/hon.3208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 15.07.2023. Verfasst von Camille Perroud und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Until now, next generation sequencing (NGS) data has not been incorporated into any prognostic stratification of multiple myeloma (MM) and no therapeutic considerations are based upon it. In this work, we correlated NGS data with (1) therapy response and survival parameters in newly diagnosed multiple myeloma, treated by VRd * and (2) MM disease stage: newly diagnosed multiple myeloma (ndMM) versus relapsed and/or refractory (relapsed/refractory multiple myeloma). We analyzed 126 patients, with ndMM and relapsed refractory multiple myeloma (rrMM), treated at the University Hospital of Bern (Inselspital). Next generation sequencing was performed on bone marrow, as part of routine diagnostics. The NGS panel comprised eight genes CCND1 , DIS3 , EGR1 , FAM4 6C (TENT5C) , FGFR3 , PRDM1 , TP53 , TRAF3 and seven hotspots in BRAF , IDH1 , IDH2 , IRF4 , KRAS , NRAS . The primary endpoint was complete remission (CR) after VRd in ndMM, in correlation with mutational profile. Mutational load was generally higher in rrMM, with more frequently mutated TP53 : 11/87 (13%) in ndMM versus 9/11 (81%) in rrMM (OR 0.0857, p = 0.0007). In ndMM, treated by VRd, mutations in MAPK‐pathway members ( NRAS, KRAS or BRAF ) were associated with reduced probability of CR (21/38, 55%), as compared with wild type NRAS, KRAS or BRAF (34/40, 85%; OR 0.2225, p = 0.006). NRAS c.181C > A (p.Q61K) as a single mutation event showed a trend to reduced probability of achieving CR (OR 0.0912, p = 0.0247). Activation of MAPK pathway via mutated NRAS , KRAS and BRAF genes seems to have a negative impact on outcome in ndMM patients receiving VRd therapy. VRd* ‐ bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital of Bern, Bern, Switzerland.
- Department of Internal Medicine, Hôpital Cantonal Fribourgeois HFR, Fribourg, Switzerland.
- Department of Internal Medicine, Spital Thun STS AG, Thun, Switzerland.
- Clinical Trials Unit, University of Bern, Bern, Switzerland.
- Department of Hematology, Kantonsspital Luzern and University of Bern, Luzern, Switzerland.
- Department of Clinical Oncology, Inselspital, University Hospital of Bern, Bern, Switzerland.
ORCID-Profile: Martin Andres, Ulrike Bacher, Thomas Pabst, Ekaterina Rebmann
Zitieren
APA
Perroud, C., Thurian, D., Andres, M., Künzi, A., Wiedemann, G., Zeerleder, S., Bacher, U., Pabst, T., Banz, Y., Porret, N., & Rebmann, E. (2023). Effect of MAPK activation via mutations in NRAS , KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma. Hematological Oncology, 41(5), 912-921. https://doi.org/10.1002/hon.3208
Vancouver
Perroud C, Thurian D, Andres M, Künzi A, Wiedemann G, Zeerleder S, et al. Effect of MAPK activation via mutations in NRAS , KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma. Hematological Oncology. 2023;41(5):912-921. doi:10.1002/hon.3208
BibTeX
@article{Perroud2023,
author = {Perroud, Camille and Thurian, Dario and Andres, Martin and Künzi, Arnaud and Wiedemann, Gertrud and Zeerleder, Sacha and Bacher, Ulrike and Pabst, Thomas and Banz, Yara and Porret, Naomi and Rebmann, Ekaterina},
title = {Effect of MAPK activation via mutations in NRAS , KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma},
journal = {Hematological Oncology},
year = {2023},
volume = {41},
number = {5},
pages = {912--921},
doi = {10.1002/hon.3208}
}
EUVIMED